Related Experiment Video
Updated: Nov 19, 2025
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events
Ryo Takai1, Yohei Funakoshi2, Hirotaka Suto3
1Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Background/Aim:
Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor (sIL-2R).
Patients And Methods:
We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured.
Results:
Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade ≥2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated.
Conclusion:
Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.
